Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Bérénice Giraud, Guillaume Hebert, Alain Deroussent, Gareth J Veal, Gilles Vassal & Angelo Paci. (2010) Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism & Toxicology 6:8, pages 919-938.
Read now
Read now
Pamela J Russell & Aparajita Khatri. (2006) Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opinion on Investigational Drugs 15:8, pages 947-961.
Read now
Read now
Jing Zhang, Quan Tian, Sui Yung Chan, Shu Chuen Li, Shufeng Zhou, Wei Duan & Yi-Zhun Zhu. (2005) Metabolism and Transport of Oxazaphosphorines and the Clinical Implications. Drug Metabolism Reviews 37:4, pages 611-703.
Read now
Read now
Articles from other publishers (22)
Rishabh Kaushik, Sheeza Khan, Meesha Sharma, Srinivasan Hemalatha, Zeba Mueed & Nitesh K. Poddar. (2020) Role of Cytochrome P450 in Prostate Cancer and its Therapy. Current Enzyme Inhibition 16:1, pages 63-73.
Crossref
Crossref
James C Neil. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
10
.
Zahra Karjoo, Vidya Ganapathy & Arash Hatefi. 2014. Gene Therapy of Cancer. Gene Therapy of Cancer
77
91
.
M.G. Bourke, S. Salwa, K.J. Harrington, M.J. Kucharczyk, P.F. Forde, M. de Kruijf, D. Soden, M. Tangney, J.K. Collins & G.C. O’Sullivan. (2011) The emerging role of viruses in the treatment of solid tumours. Cancer Treatment Reviews 37:8, pages 618-632.
Crossref
Crossref
G. Gonzalez-Aseguinolaza, J. Prieto & R. Hernandez-Alcoceba. (2011) Gene therapy of liver cancer: an updateThérapie génique du cancer du foie : le point. Journal Africain du Cancer / African Journal of Cancer 3:3, pages 180-192.
Crossref
Crossref
Rubi Mahato, Wanyi Tai & Kun Cheng. (2011) Prodrugs for improving tumor targetability and efficiency. Advanced Drug Delivery Reviews 63:8, pages 659-670.
Crossref
Crossref
Peter Hlavica. (2009) Assembly of non-natural electron transfer conduits in the cytochrome P450 system: A critical assessment and update of artificial redox constructs amenable to exploitation in biotechnological areas. Biotechnology Advances 27:2, pages 103-121.
Crossref
Crossref
Monica Stewart, Nancy Mackay, Linda Hanlon, Karen Blyth, Linda Scobie, Ewan Cameron & James C. Neil. (2007)
Insertional Mutagenesis Reveals Progression Genes and Checkpoints in
MYC/Runx2
Lymphomas
. Cancer Research 67:11, pages 5126-5133.
Crossref
Crossref
Daniel Portsmouth, Juraj Hlavaty & Matthias Renner. (2007) Suicide genes for cancer therapy. Molecular Aspects of Medicine 28:1, pages 4-41.
Crossref
Crossref
Rubén Hernández-Alcoceba, Bruno Sangro & Jesús Prieto. (2007) Gene therapy of liver cancer. Annals of Hepatology 6:1, pages 5-14.
Crossref
Crossref
Youssef Jounaidi, Chong-Sheng Chen, Gareth J. Veal & David J. Waxman. (2006)
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low
K
m cyclophosphamide 4-hydroxylase P450 2B11
. Molecular Cancer Therapeutics 5:3, pages 541-555.
Crossref
Crossref
Partha Roy & David J. Waxman. (2006) Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer. Toxicology in Vitro 20:2, pages 176-186.
Crossref
Crossref
Ruben Hernandez-Alcoceba. (2006) Gene therapy of liver cancer. World Journal of Gastroenterology 12:38, pages 6085.
Crossref
Crossref
Lawrence S Young, Peter F Searle, David Onion & Vivien Mautner. (2006) Viral gene therapy strategies: from basic science to clinical application. The Journal of Pathology 208:2, pages 299-318.
Crossref
Crossref
Meera Kumarakulasingham, Patrick H. Rooney, Sinclair R. Dundas, Colin Telfer, William T. Melvin, Stephanie Curran & Graeme I. Murray. (2005) Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis. Clinical Cancer Research 11:10, pages 3758-3765.
Crossref
Crossref
Marina Tychopoulos, Laurent Corcos, Philippe Genne, Philippe Beaune & Isabelle de Waziers. (2005) A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Therapy 12:5, pages 497-508.
Crossref
Crossref
Christopher M. Halloran, Paula Ghaneh, Eithne Costello & John P. Neoptolemos. (2005) Trials of gene therapy for pancreatic carcinoma. Current Gastroenterology Reports 7:3, pages 165-169.
Crossref
Crossref
Jeremy P. Braybrooke, Andrew Slade, Gael Deplanque, Richard Harrop, Srinivasan Madhusudan, Martin D. Forster, Rachel Gibson, Andreas Makris, Denis C. Talbot, Jan Steiner, Linda White, On Kan, Stuart Naylor, Miles W. Carroll, Sue M. Kingsman & Adrian L. Harris. (2005) Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Clinical Cancer Research 11:4, pages 1512-1520.
Crossref
Crossref
Bertrand Rochat. (2005) Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance. Clinical Pharmacokinetics 44:4, pages 349-366.
Crossref
Crossref
M. B. Nthangeni, P. Urban, D. Pompon, M. S. Smit & J.‐M. Nicaud. (2004)
The use of
Yarrowia lipolytica
for the expression of human cytochrome P450 CYP1A1
. Yeast 21:7, pages 583-592.
Crossref
Crossref
Morag C. E. McFadyen, William T. Melvin & Graeme I. Murray. (2004)
Cytochrome
P
450 enzymes: Novel options for cancer therapeutics
. Molecular Cancer Therapeutics 3:3, pages 363-371.
Crossref
Crossref
Hans E. J. Hofland, Frank L. Sorgi & Edward G. Spack. 2004. Cellular Drug Delivery. Cellular Drug Delivery
67
80
.